 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...4445464748495051525354...8687» |
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Maxillar osteonecrosis related to denosumab. Evaluation of nine cases. (Pubmed Central) - May 15, 2021
No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Is it necessary to modify the clinical trials about osteoporosis? The serious problem of denosumab. (Pubmed Central) - May 15, 2021
No abstract available No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Role of bone-modifying agents in advanced cancer. (Pubmed Central) - May 15, 2021
In order to reduce the risk of these complications, the supportive treatment of patients with bone lesions from advanced cancer typically includes the use of bone-modifying agents (BMAs), specifically bisphosphonates and denosumab. The choice of specific agent, dosing schedule and duration of therapy should be individualized by taking into account disease characteristics, medication side-effect profiles and patient preferences.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. (Pubmed Central) - May 15, 2021
Confirming the above results, histochemical analysis of the bone from the combination treatment demonstrated normal bone morphology, and osteoblast and osteoclast cell activities. In conclusion, TXT-NPs and DNmb in combination, because of their complementary roles in breaking the cross talk between cancer cells and bone cells, was significantly effective in treating bone metastasis.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis. (Pubmed Central) - May 15, 2021
Some studies have indicated that concomitant treatment with antiresorptives, such as bisphosphonates or denosumab, could prevent erosive lesions in this process, and it has even been suggested that treatment with a bone forming agent, such as teriparatide, could revert previously established erosive lesions. In this article we review the evidence available on the efficacy of treatment with antiresorptives and bone forming agents in the prevention and/or treatment of bone erosions associated with RA.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. (Pubmed Central) - May 15, 2021
In this article we review the evidence available on the efficacy of treatment with antiresorptives and bone forming agents in the prevention and/or treatment of bone erosions associated with RA. These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Oral cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy. (Pubmed Central) - May 15, 2021
Furthermore, we hypothesize that this effect is primarily mediated by cinacalcet's interaction with the calcium-sensing receptor in the intestine with lesser effects at bone and kidney. Lastly, the role of 1,25-dihydroxyvitamin D in hypercalcemia malignancy may be underappreciated in solid tumors.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Clinical, radiological and pathological outcomes following treatment of primary giant cell tumour of bone with Denosumab. (Pubmed Central) - May 15, 2021
Of concern we noted a trend towards increasing recurrence rates with the potential risk for rapid relapse. Furthermore, two cases experienced sarcomatous transformation, which is a growing area of concern within the literature.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report. (Pubmed Central) - May 15, 2021
Better understanding of the various presentations of the rebound effect after stopping treatment with denosumab would improve diagnostic management of misleading forms, as in this case. Bisphosphonates could partially prevent this rebound effect.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Optimising the management of osteoporosis. (Pubmed Central) - May 15, 2021
Oral bisphosphonates remain the most cost-effective first line of treatment. Better methods of identifying patients with high fracture risk is needed as there is adequate effective treatment for osteoporosis.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Effects of denosumab treatment in chronic liver disease patients with osteoporosis. (Pubmed Central) - May 15, 2021
Better methods of identifying patients with high fracture risk is needed as there is adequate effective treatment for osteoporosis. Denosumab treatment was safe and increased BMD, suppressed bone turnover, and improved bone quality marker levels in CLD patients with osteoporosis, irrespective of differences in baseline characteristics.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
PK/PD data, Journal: Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis. (Pubmed Central) - May 15, 2021
Finally, we identify a treatment case most promising for achieving maintenance of BMD and mineral content, while moderately increasing BTMs. The latter case uses no drug holiday, but reduces the most commonly prescribed denosumab dose (60 mg every 6 months) by half at same interval.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study. (Pubmed Central) - May 15, 2021
Short-term treatment with TPTD caused mild improvement in femur neck BMD compared with DMab alone. However, further research with a longer duration of TPTD treatment is warranted, as our findings lack statistical significance.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: An Approach for the Prevention, Diagnosis, and Treatment of Jaw Osteonecrosis: Report of a Case Associated with Zoledronic Acid. (Pubmed Central) - May 15, 2021
CONCLUSIONS Osteonecrosis of the jaw can be prevented through infection control and local trauma prevention. Patients who are taking antiresorptive drugs must receive special care from dental surgeons and doctors, and receive the necessary oral treatments before starting drug therapy.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. (Pubmed Central) - May 15, 2021
Patients who are taking antiresorptive drugs must receive special care from dental surgeons and doctors, and receive the necessary oral treatments before starting drug therapy. If this hypothesis is verified, denosumab, an established anti-osteoporotic medication, may be considered as a candidate for NASH in drug-repurposing studies.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Comparing the Surgical Response of Bisphosphonate-Related Versus Bisphosphonate-Related Osteonecrosis of the Jaws. (Pubmed Central) - May 15, 2021
If this hypothesis is verified, denosumab, an established anti-osteoporotic medication, may be considered as a candidate for NASH in drug-repurposing studies. The surgical success rate for MRONJ secondary to denosumab was 80.0%, similar to that reported in bisphosphonates of 85 to 95%; however, more evidence must be reported and analyzed.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone. (Pubmed Central) - May 15, 2021
This novel approach may allow for more joint sparing strategies in the future for other patients in this difficult situation. Further cases will need to be gathered to establish this technique as a suitable treatment pathway.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: A bedridden young lady with hypophosphatemic rickets treated with denosumab: a case report. (Pubmed Central) - May 15, 2021
Denosumab is an effective treatment for osteoporosis, we used it in our patient in addition to calcitriol because she had severe osteoporosis due to long standing hypophosphatemic rickets that had not been treated properly, the patient improved markedly and regained the ability to walk again after being bedridden for 4 years. It may be a drug to consider in such cases although further studies need to be done to confirm this.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Cosentyx (secukinumab) / Novartis
Clinical, Journal: Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab. (Pubmed Central) - May 15, 2021
Radiologists, surgeons, and pathologists should be aware of this interaction, which can cause lesional ossification. Further research is required to define the therapeutic potential of this drug for GCTB and osteolytic disease.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review. (Pubmed Central) - May 15, 2021
Bone loss due to infections involves the suppression of osteoblastogenesis by osteoblast apoptosis, which is induced by the nuclear factor-κB and mitogen-activated protein kinase pathways, and osteoclastogenesis with the receptor activator of the nuclear factor-κB ligand-receptor combination and subsequent activation of the nuclear factor of activated T cells cytoplasmic 1 and c-Fos. In this study, we review and discuss the molecular mechanisms of bone loss secondary to infection and analyze the efficacy of the medications for osteoporosis, focusing on romosozumab, teriparatide, denosumab, and bisphosphonates, in treating this pathological condition.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
[VIRTUAL] Evaluation of medication-related osteonecrosis of the jaw in patients receiving bone-modifying agents for bone metastases and multiple myeloma () - May 14, 2021 - Abstract #FLASCOSpring2021FLASCO_Spring_34;
The incidence of MRONJ was higher amongst denosumab patients than in the zoledronic acid group. This demonstrates the importance of baseline dental examinations and monitoring throughout treatment with bone-modifying therapies to prevent MRONJ.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw. (Pubmed Central) - May 14, 2021
This demonstrates the importance of baseline dental examinations and monitoring throughout treatment with bone-modifying therapies to prevent MRONJ. In the conservative treatment of ARONJ, the administration of several BMAs and anti-VEGFR drugs was the factor contributing to the inhibition of healing.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, P4 data, Journal: Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. (Pubmed Central) - May 14, 2021
This study confirmed the long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis in daily clinical practice. No new safety signals were identified.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Review, Journal: Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases. (Pubmed Central) - May 14, 2021
This success has renewed interest in targeted alpha-particle therapy development for visceral and bone metastasis. This review will discuss (i) the biology of bone metastasis, especially focusing on the vicious cycle of bone metastasis, (ii) how bone remodeling has been exploited to administer systemic radiotherapies, and (iii) targeted radiotherapy development and progress in the development of targeted alpha-particle therapy for the treatment of prostate cancer bone metastasis.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Clinical, Journal, Adverse events, Real-world evidence: Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study. (Pubmed Central) - May 14, 2021
Sixty-four (27.8%) of 230 patients experienced an adverse event, and 7 (3.0%) new fractures were recorded. In sum, romosozumab treatment for 12 months significantly improved lumbar spine, total hip, and femoral neck BMD according to real-world data.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal: Reciprocal interactions between osteoclasts and nociceptive sensory neurons in bone cancer pain. (Pubmed Central) - May 14, 2021
Furthermore, we highlight how this perturbed state of osteoclast overactivation contributes to bone cancer pain through (1) direct mechanisms, through their production of pronociceptive factors that act directly on sensory afferents; and (2) by indirect mechanisms, wherein osteoclasts drive bone resorption that weakens tumor-bearing bones and predisposes them to skeletal-related events, thereby driving bone cancer pain and functional impairment. Finally, we discuss some potential therapeutic agents, such as denosumab, bisphosphonates, and nivolumab, and discuss their respective effects on bone cancer pain, osteoclast overactivation, and tumor growth within the bone TME.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - May 13, 2021
P1, N=75, Active, not recruiting, Sponsor: Massachusetts General Hospital
Finally, we discuss some potential therapeutic agents, such as denosumab, bisphosphonates, and nivolumab, and discuss their respective effects on bone cancer pain, osteoclast overactivation, and tumor growth within the bone TME. Trial completion date: Oct 2021 --> Jul 2021 | Trial primary completion date: Oct 2020 --> Jul 2021
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal, HEOR: Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand. (Pubmed Central) - May 12, 2021
The fracture risk was not adjusted to reflect potential changes in risk after denosumab treatment discontinuation.Conclusions. In Thailand, denosumab offers a cost-effective osteoporosis treatment option versus no pharmacologic treatment in postmenopausal women at high risk of fracture.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Bone Mineral Density - Clinical Relevance and Quantitative Assessment. (Pubmed Central) - May 12, 2021
In the case of denosumab, it is now apparent that stopping therapy at any point can lead to an increase in multiple fracture risk. For patients who do not respond to antiosteoporosis pharmacologic therapy, with an improvement in BMD or an incident fragility fracture, other intervening issues, such as vitamin D deficiency, and/or compliance should be considered.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, P2 data, Journal: Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. (Pubmed Central) - May 12, 2021
P2
Although rare, GCTB can undergo malignant transformation, and rates in this study were consistent with previous reports. Signs of poor mineralization or lack of response to denosumab treatment may warrant close monitoring.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: RANKL regulates male reproductive function. (Pubmed Central) - May 11, 2021
In infertile men, one dose of Denosumab decreases RANKL seminal fluid concentration and increases serum Inhibin-B and anti-Müllerian-hormone levels, but semen quality only in a subgroup. This translational study suggests that RANKL is a regulator of male reproductive function, however, predictive biomarkers for treatment-outcome requires further investigation in placebo-controlled studies.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency. (Pubmed Central) - May 8, 2021
Recent findings suggest a possible alternative explanation for BPs role in this pattern. In the present work we discuss how a condition of osteomalacia and low vitamin D levels might be determinant factors.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. (Pubmed Central) - May 6, 2021
P3
In the present work we discuss how a condition of osteomalacia and low vitamin D levels might be determinant factors. In RA patients treated with csDMARDs, new bone erosion predictors were seropositivity, elevated inflammatory markers, and baseline ES ≥3.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, IO biomarker: Immuno-PET Molecular Imaging of RANKL in Cancer. (Pubmed Central) - May 6, 2021
In RA patients treated with csDMARDs, new bone erosion predictors were seropositivity, elevated inflammatory markers, and baseline ES ≥3. [Zr]Zr-DFO-AMG162 can detect heterogeneous RANKL expression in the TME of human cancer xenografts, supporting further translation of RANKL immuno-PET to evaluate tumor RANKL distribution in patients.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Review, Journal: Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. (Pubmed Central) - May 6, 2021
In postmenopausal women, either denosumab or BPs can be prescribed for fracture prevention with pertinent attention to the rebound phenomenon after stopping denosumab. Adjuvant BPs, in contrast to denosumab, have shown high level evidence for reducing breast cancer recurrence in high-risk post-MP women which should be taken into account when choosing between these two.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Treating Osteoporotic Osteoarthritis, or the Art of Cutting a Balding Man´s Hair. (Pubmed Central) - May 5, 2021
Adjuvant BPs, in contrast to denosumab, have shown high level evidence for reducing breast cancer recurrence in high-risk post-MP women which should be taken into account when choosing between these two. No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Retrospective data, Journal: Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study. (Pubmed Central) - May 5, 2021
Changes in BSAP and P1NP showed promise in short-term prediction of BMD. We suggest further trials expanding on the knowledge of these BTMs with assessment of fracture risk, sequential measurements of BTMs within the first 6 months, and the additional use of computed tomography to assess BMD.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Proposal for a preventive protocol for medication-related osteonecrosis of the jaw. (Pubmed Central) - May 5, 2021
Along with a team of well-educated and trained dentists, it is equally important to maintain contact with the medical team involved in the treatment of the underlying pathology, especially rheumatologists, oncologists, internists and gynaecologists. All the above requires a great staff learning and organization effort, continuous training and coordination of the whole team involved in the preventive management of these patients.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Preclinical, Journal: Beneficial effects of anti-RANKL antibody in depression-like phenotype, inflammatory bone markers, and bone mineral density in male susceptible mice after chronic social defeat stress. (Pubmed Central) - May 4, 2021
These findings demonstrate that anti-RANKL may have beneficial effects in depression-like phenotype and abnormalities in bone functions of CSDS susceptible mice. It is, therefore, likely that anti-human RANKL antibody (i.e., Denosumab) would be a potential therapeutic drug for depression and osteoporosis.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Management of glucocorticoid-induced osteoporosis. (Pubmed Central) - May 4, 2021
General measures include to prescribe the lowest dose of GC to control the underlying disease for the shortest possible time, maintain adequate vitamin D levels and calcium intake, maintain mobility, and prescribe a bone acting agent in patients at high risk of fracture. These agents include oral and intravenous bisphosphonates, denosumab, and teriparatide.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women. (Pubmed Central) - May 4, 2021
Finally, denosumab did not cause excess risks of adverse events. These findings suggested that postmenopausal women receiving denosumab had increased BMDs and reduced fractures at various sites without inducing any adverse events.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management. (Pubmed Central) - May 1, 2021
Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: New Perspective for Soft Tissue Closure in Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Barbed Sutures. (Pubmed Central) - May 1, 2021
Within the limits of a retrospective study, BS showed a high success rate and are therefore recommended for soft tissue closure of exposed jawbone sites in MRONJ patients. Additional studies are warranted to further evaluate this novel application of BS.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Persistent urinary phosphate wasting in a patient with metastatic breast cancer: What's your diagnosis? (Pubmed Central) - Apr 30, 2021
The patient required intensive intravenous and oral phosphate supplementation in addition to vitamin D repletion. A high index of clinical suspicion can yield the correct diagnosis where TIO arises in the setting of a solid organ tumor and help the clinician appropriately manage these challenging cases.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer. (Pubmed Central) - Apr 30, 2021
TIO in breast cancer poses a distinct diagnostic challenge due to the common adjunct oncologic management with bone protection therapy such as denosumab or bisphosphonates...Delay of diagnosis of TIO can result in worsening functional status, and early morbidity and mortality. To date, there has been one prior case report of TIO in breast cancer, and herein we describe two additional cases of TIO in this setting.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Ⅱ. Success and Limitations of Denosumab for Giant Cell Tumor of Bone (Pubmed Central) - Apr 30, 2021
To date, there has been one prior case report of TIO in breast cancer, and herein we describe two additional cases of TIO in this setting. No abstract available
- Prolia (denosumab) / Amgen, Daiichi Sankyo
[VIRTUAL] Clinical behavior of advanced giant cell tumor: 15 years observation study in N.N. Blokhin National Medical Research Center of Oncology. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5548;
Surgeries in history and tumor localization were associated with higher risk of metastasis . Denosumab for advanced GCT is a choice of treatment, we wasn’t observed any cases of GCT malignant transformation during denosumab treatment .
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Does denosumab offer survival benefits? Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_5254;
Patients receiving combination therapy did not perform poorly despite of poor prognostic features such as brain metastases and numerous skeletal metastases . Although we did notice potential benefit of the longer duration of concomitant use of ICI and denosumab, future prospective clinical trials are needed to evaluate the synergistic effect of RANKL inhibitors/ICI and if duration of RANKL inhibitors matters.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
[VIRTUAL] Bone-targeted therapy in patients with renal cell carcinoma bone metastases undergoing palliative surgery. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4492;
Post-op denosumab was associated with better PFS and OS compared to bisphosphonates and bisphosphonates were associated with worse PFS and OS compared to no bone-targeted therapy . Patient selection for therapy may be an important source of bias .
- || Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo
Clinical, Journal: Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis. (Pubmed Central) - Apr 29, 2021
Patient selection for therapy may be an important source of bias . Prolonged disease duration, low BMI, and low total hip BMD could be risk factors of vertebral fracture in patients on glucocorticoid treatment for rheumatological diseases.